How do physicians participate and identify patients who might benefit?

Convalescent plasma protocol requirements

Photo of physicians

This treatment protocol requires that physicians register their institution, themselves and potential patients in Mayo Clinic's database in order to obtain access to convalescent plasma for their patients. Enroll patients in the EAP only after your hospital and you are registered.

Patients or their families cannot self-refer into this protocol.

Using the robust database, patients can best be matched with plasma stores and receive the fastest possible treatment.

Other information to be collected retrospectively will include patient demographics, acute care facility resource utilization (such as total length of stay, days in ICU, days intubated and survival to discharge from an acute care facility).

Mayo Clinic is a nationally recognized IRB by the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP). Your registration creates and signifies your agreement with the protocol documents.

After you register your medical facility, yourself and your patient, the online tool will create a patient identification number to match with plasma.

Mayo Clinic will contact you to fill out short regulatory documents for you and your patient.

Please use your most frequently monitored email address and provide your personal cell phone number so Mayo can connect with you as quickly as possible.

What patients are eligible to receive convalescent plasma in this protocol?

The protocol requires the patient family member to consent to receiving plasma from someone who has recovered from COVID-19. Their plasma has substances that could improve chances of recovery. Only hospitalized patients referred by their health care provider will participate in this protocol.

Hospitalized patients are eligible to receive convalescent plasma if:

Severe COVID-19 is defined by one or more of the following:

Life-threatening COVID-19 is defined as one or more of the following:

How to enroll your patient(s) in the COVID-19 plasma treatment study